StockMacro
Menu

Biogen

$249.59 +29% in 6 monthsMarket cap $36.9B

BIIB on XNAS, Health Care, Biogen Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 11% to $2.8B, but net income fell 78% over 12 months while shares gained 48% in a year.

  • WatchTwelve-month revenue rose just 2.3% to $10.3B, well below the quarter
  • BadForeign specialist visa applications fell 21%, to 79 from 100

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
7,500
Website
biogen.com
Listed
Nasdaq, US
Last results
28 Oct 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.8B, net loss $20.6M.
Quarter to 31 Dec 2021: revenue $2.7B, net income $368.2MQuarter to 31 Dec 2021: revenue $2.7B, net income $368.2MQuarter to 31 Mar 2022: revenue $2.5B, net income $303.8MQuarter to 31 Mar 2022: revenue $2.5B, net income $303.8MQuarter to 30 Jun 2022: revenue $2.6B, net income $1.1BQuarter to 30 Jun 2022: revenue $2.6B, net income $1.1BQuarter to 30 Sep 2022: revenue $2.5B, net income $1.1BQuarter to 30 Sep 2022: revenue $2.5B, net income $1.1BQuarter to 31 Dec 2022: revenue $2.5B, net income $550.4MQuarter to 31 Dec 2022: revenue $2.5B, net income $550.4MQuarter to 31 Mar 2023: revenue $2.5B, net income $387.9MQuarter to 31 Mar 2023: revenue $2.5B, net income $387.9MQuarter to 30 Jun 2023: revenue $2.5B, net income $591.6MQuarter to 30 Jun 2023: revenue $2.5B, net income $591.6MQuarter to 30 Sep 2023: revenue $2.5B, net income -$68.1MQuarter to 30 Sep 2023: revenue $2.5B, net income -$68.1MQuarter to 31 Dec 2023: revenue $2.4B, net income $249.7MQuarter to 31 Dec 2023: revenue $2.4B, net income $249.7MQuarter to 31 Mar 2024: revenue $2.3B, net income $393.4MQuarter to 31 Mar 2024: revenue $2.3B, net income $393.4MQuarter to 30 Jun 2024: revenue $2.5B, net income $583.6MQuarter to 30 Jun 2024: revenue $2.5B, net income $583.6MQuarter to 30 Sep 2024: revenue $2.5B, net income $388.5MQuarter to 30 Sep 2024: revenue $2.5B, net income $388.5MQuarter to 31 Dec 2024: revenue $2.5B, net income $266.7MQuarter to 31 Dec 2024: revenue $2.5B, net income $266.7MQuarter to 31 Mar 2025: revenue $2.4B, net income $240.5MQuarter to 31 Mar 2025: revenue $2.4B, net income $240.5MQuarter to 30 Jun 2025: revenue $2.6B, net income $634.8MQuarter to 30 Jun 2025: revenue $2.6B, net income $634.8MQuarter to 30 Sep 2025: revenue $2.5B, net income $466.5MQuarter to 30 Sep 2025: revenue $2.5B, net income $466.5MQuarter to 31 Dec 2025: revenue $2.3B, net income -$48.9MQuarter to 31 Dec 2025: revenue $2.3B, net income -$48.9MQuarter to 31 Mar 2026: revenue $2.5B, net income $319.5MQuarter to 31 Mar 2026: revenue $2.5B, net income $319.5MQuarter to 30 Jun 2026: revenue $2.7B, net income $97.5MQuarter to 30 Jun 2026: revenue $2.7B, net income $97.5MQuarter to 30 Sep 2026: revenue $2.8B, net income -$20.6MQuarter to 30 Sep 2026: revenue $2.8B, net income -$20.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $2.8B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$2.8B-$20.6M
30 Jun 2026$2.7B$97.5M
31 Mar 2026$2.5B$319.5M
31 Dec 2025$2.3B-$48.9M
30 Sep 2025$2.5B$466.5M
30 Jun 2025$2.6B$634.8M
31 Mar 2025$2.4B$240.5M
31 Dec 2024$2.5B$266.7M
30 Sep 2024$2.5B$388.5M
30 Jun 2024$2.5B$583.6M
31 Mar 2024$2.3B$393.4M
31 Dec 2023$2.4B$249.7M
30 Sep 2023$2.5B-$68.1M
30 Jun 2023$2.5B$591.6M
31 Mar 2023$2.5B$387.9M
31 Dec 2022$2.5B$550.4M
30 Sep 2022$2.5B$1.1B
30 Jun 2022$2.6B$1.1B
31 Mar 2022$2.5B$303.8M
31 Dec 2021$2.7B$368.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $10.3B $10.1B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +2.3% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $347.5M $1.6B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.32 $10.97
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 74.0% 75.2% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 3.4% 16.0% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 1.9% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $2.1B $2.3B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.3B $4.0B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $6.3B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – $2.3B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $128.01
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 106 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.6 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.9 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
BiogenBIIB (this company) $36.9B1063.6+2.3%3.4%
Revolution MedicinesRVMD $34.9Bloss–––
ModernaMRNA $78.9Bloss31.2+13%-110%
ExelixisEXEL $15.8B17.86.3+9.1%35.5%
Neurocrine BiosciencesNBIX $15.2B21.74.1+38%19.0%
Bio-TechneTECH $11.4B66.49.3+0.9%14.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+2.4%

1,044 13F filers vs 1,020

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

95%

140.0M shares held by 13F filers (30 Sep 2026) of 147.8M outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.7%

5.5M shares sold short (30 Oct 2026) of 147.8M outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.0

5.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-0.9%

5.5M shares sold short in the report before, 5.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

68%

68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 59%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-21%

79 vs 100 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+11%

$2.8B vs $2.5B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-13%

$40.4M vs $46.2M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$4.2M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

33

33 articles in the last 7 days; its usual week has 6.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.1×

33 articles in the last 7 days; its usual week has 6.5.

Price $249.59 on 20 Nov 2026, +48% over 12 months (12-month range $164.42 to $254.87)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $905K in the last 12 months (the 12 months before: -$2.0M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 79 published in the last 12 months, -21% on the 12 months before.
Revenue per quarter. Revenue $2.8B in the latest quarter, +11% on a year earlier.
Capital spending per quarter. Capital spending $40.4M in the latest quarter, -13% on a year earlier.
Institutional holders (13F filers). 1,044 13F filers reported holding it in the latest 13F quarter, +23% on a year earlier.
Lobbying spend. Lobbying spend: $4.2M published in the last 12 months, +2.0% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
14 May 20268-K and other filingsCompleted an acquisition or asset sale
11 Mar 20268-K and other filingsDirector or officer change
11 Feb 20268-K and other filingsDirector or officer change
11 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Jan 2026Lobbying filinglobbying engagement terminated (JEFFREY J. KIMBELL & ASSOCIATES, INC.)
30 Dec 2025Sharp changeShort interest spike: short interest spike, 6.6M vs usual 3.8M (2025-12-15); 2.6x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 6.8M vs usual 3.8M (2025-11-28); 2.5x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 6.1M vs usual 3.8M (2025-11-14); 2.3x the same period a year earlier
1 Jul 2025Lobbying filingnew lobbying registration (DLA PIPER LLP (US))
22 Jan 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MAN (2024-12-31)
15 Jan 20258-K and other filingsDirector or officer change
30 Oct 20248-K and other filingsDirector or officer change
12 Sep 20248-K and other filingsDirector or officer change
12 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 20248-K and other filingsA major agreement ended
23 Jul 2024Sharp changeLobbying spend jump: lobbying spend jump, 1.7M vs usual 940K (2024-06-30); 2.0x the same period a year earlier
23 Jan 2024Sharp changeLobbying on a new issue: lobbying on a new issue: TRA (2023-12-31)
22 Jan 2024Lobbying filinglobbying engagement terminated (THORN RUN PARTNERS)
8 Nov 20238-K and other filingsDirector or officer change
8 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Aug 2023Sharp changeShort interest spike: short interest spike, 3.4M vs usual 2.1M (2023-07-31); 1.8x the same period a year earlier
18 Apr 2023Lobbying filinglobbying engagement terminated (CLYBURN CONSULTING, LLC)
9 Mar 20238-K and other filingsDirector or officer change
9 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 2023Lobbying filinglobbying engagement terminated (CAPITOL COUNSEL LLC)
10 Nov 20228-K and other filingsDirector or officer change
10 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jun 20228-K and other filingsDirector or officer change
3 May 20228-K and other filingsDirector or officer change
3 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Apr 2022Lobbying filingnew lobbying registration (CLYBURN CONSULTING, LLC)
31 Jan 20228-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Oct 2022: -$1.6M published
Month from 1 Dec 2022: -$1.7M published
Month from 1 Mar 2023: -$153K published
Month from 1 Apr 2023: -$25K published
Month from 1 May 2023: -$804K published
Month from 1 Jul 2023: -$23K published
Month from 1 Sep 2023: -$116K published
Month from 1 Dec 2023: -$27K published
Month from 1 Feb 2024: -$237K published
Month from 1 Apr 2024: -$20K published
Month from 1 Sep 2024: -$88K published
Month from 1 Dec 2024: -$17K published
Month from 1 Mar 2025: -$1.3M published
Month from 1 May 2025: -$329K published
Month from 1 Jul 2025: -$300K published
Month from 1 Sep 2025: -$69K published
Month from 1 Feb 2026: -$665K published
Month from 1 Aug 2026: -$240K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 20 published
Quarter from 1 Apr 2022: 70 published
Quarter from 1 Jul 2022: 19 published
Quarter from 1 Oct 2022: 21 published
Quarter from 1 Jan 2023: 21 published
Quarter from 1 Apr 2023: 63 published
Quarter from 1 Jul 2023: 11 published
Quarter from 1 Oct 2023: 8 published
Quarter from 1 Jan 2024: 10 published
Quarter from 1 Apr 2024: 47 published
Quarter from 1 Jul 2024: 26 published
Quarter from 1 Oct 2024: 12 published
Quarter from 1 Jan 2025: 14 published
Quarter from 1 Apr 2025: 33 published
Quarter from 1 Jul 2025: 35 published
Quarter from 1 Oct 2025: 18 published
Quarter from 1 Jan 2026: 5 published
Quarter from 1 Apr 2026: 28 published
Quarter from 1 Jul 2026: 28 published
Quarter from 1 Oct 2026: 18 published
Revenue per quarter
Quarter ended 31 Dec 2021: $2.7B, -4.2% on a year earlier; public on 4 Feb 2022
Quarter ended 31 Mar 2022: $2.5B, -6.0% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $2.6B, -6.7% on a year earlier; public on 21 Jul 2022
Quarter ended 30 Sep 2022: $2.5B, -9.7% on a year earlier; public on 26 Oct 2022
Quarter ended 31 Dec 2022: $2.5B, -6.9% on a year earlier; public on 16 Feb 2023
Quarter ended 31 Mar 2023: $2.5B, -2.7% on a year earlier; public on 26 Apr 2023
Quarter ended 30 Jun 2023: $2.5B, -5.1% on a year earlier; public on 26 Jul 2023
Quarter ended 30 Sep 2023: $2.5B, +0.9% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $2.4B, -6.2% on a year earlier; public on 15 Feb 2024
Quarter ended 31 Mar 2024: $2.3B, -7.0% on a year earlier; public on 25 Apr 2024
Quarter ended 30 Jun 2024: $2.5B, +0.4% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $2.5B, -2.5% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $2.5B, +2.9% on a year earlier; public on 13 Feb 2025
Quarter ended 31 Mar 2025: $2.4B, +6.1% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $2.6B, +7.3% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $2.5B, +2.8% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $2.3B, -7.1% on a year earlier; public on 7 Feb 2026
Quarter ended 31 Mar 2026: $2.5B, +1.9% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $2.7B, +3.4% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $2.8B, +11% on a year earlier; public on 29 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $51.6M, -40% on a year earlier; public on 4 Feb 2022
Quarter ended 31 Mar 2022: $57.9M, -37% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $36.9M, -49% on a year earlier; public on 21 Jul 2022
Quarter ended 30 Sep 2022: $59.1M, +41% on a year earlier; public on 26 Oct 2022
Quarter ended 31 Dec 2022: $86.4M, +67% on a year earlier; public on 16 Feb 2023
Quarter ended 31 Mar 2023: $66.6M, +15% on a year earlier; public on 26 Apr 2023
Quarter ended 30 Jun 2023: $71.0M, +92% on a year earlier; public on 26 Jul 2023
Quarter ended 30 Sep 2023: $74.2M, +26% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $65.2M, -25% on a year earlier; public on 15 Feb 2024
Quarter ended 31 Mar 2024: $45.9M, -31% on a year earlier; public on 25 Apr 2024
Quarter ended 30 Jun 2024: $33.5M, -53% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $35.0M, -53% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $39.3M, -40% on a year earlier; public on 13 Feb 2025
Quarter ended 31 Mar 2025: $37.1M, -19% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $26.6M, -21% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $46.2M, +32% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $43.9M, +12% on a year earlier; public on 7 Feb 2026
Quarter ended 31 Mar 2026: $51.2M, +38% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $40.9M, +54% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $40.4M, -13% on a year earlier; public on 29 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 892; public on 14 Feb 2022
31 Mar 2022 report: 885; public on 16 May 2022
30 Jun 2022 report: 856; public on 15 Aug 2022
30 Sep 2022 report: 890; public on 14 Nov 2022
31 Dec 2022 report: 937; public on 14 Feb 2023
31 Mar 2023 report: 920; public on 15 May 2023
30 Jun 2023 report: 923; public on 14 Aug 2023
30 Sep 2023 report: 877; public on 14 Nov 2023
31 Dec 2023 report: 911; public on 14 Feb 2024
31 Mar 2024 report: 898; public on 15 May 2024
30 Jun 2024 report: 885; public on 14 Aug 2024
30 Sep 2024 report: 853; public on 14 Nov 2024
31 Dec 2024 report: 820; public on 14 Feb 2025
31 Mar 2025 report: 835; public on 15 May 2025
30 Jun 2025 report: 818; public on 14 Aug 2025
30 Sep 2025 report: 848; public on 14 Nov 2025
31 Dec 2025 report: 951; public on 17 Feb 2026
31 Mar 2026 report: 977; public on 15 May 2026
30 Jun 2026 report: 1,020; public on 14 Aug 2026
30 Sep 2026 report: 1,044; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $670K published
Quarter from 1 Apr 2022: $1.1M published
Quarter from 1 Jul 2022: $940K published
Quarter from 1 Oct 2022: $900K published
Quarter from 1 Jan 2023: $900K published
Quarter from 1 Apr 2023: $990K published
Quarter from 1 Jul 2023: $830K published
Quarter from 1 Oct 2023: $1.1M published
Quarter from 1 Jan 2024: $940K published
Quarter from 1 Apr 2024: $1.1M published
Quarter from 1 Jul 2024: $1.7M published
Quarter from 1 Oct 2024: $710K published
Quarter from 1 Jan 2025: $700K published
Quarter from 1 Apr 2025: $1.0M published
Quarter from 1 Jul 2025: $1.4M published
Quarter from 1 Oct 2025: $990K published
Quarter from 1 Jan 2026: $770K published
Quarter from 1 Apr 2026: $1.5M published
Quarter from 1 Jul 2026: $1.1M published
Quarter from 1 Oct 2026: $880K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $240K (5 Aug 2026), 3.1× its normal reading; higher than 61% of its own history.
  • Insider net buying (open market): Insiders sold a net $905K in the last 12 months (the 12 months before: -$2.0M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 79 published in the last 12 months, -21% on the 12 months before.
  • Revenue per quarter: Revenue $2.8B in the latest quarter, +11% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 76 insider trades

No trades in the last 90 days; the latest was filed 5 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
5 Aug 2026Lloyd MinorDirectorSellplanned in advance (10b5-1)1,186$202.15$240KForm 4
17 Feb 2026Nicole MurphyHead of Pharm Ops and TechBuy3$195.04$585Form 4
10 Feb 2026Priya SinghalHead of DevelopmentSellplanned in advance (10b5-1); after exercising options2,660$199.83$532KForm 4
3 Feb 2026Priya SinghalHead of DevelopmentSellplanned in advance (10b5-1); after exercising options748$179.30$134KForm 4
2 Sep 2025Priya SinghalHead of DevelopmentSellplanned in advance (10b5-1); after exercising options517$133.55$69KForm 4
16 Jul 2025Rachid IzzarHead of Global Product Strat.Sellplanned in advance (10b5-1)2,223$135.00$300KForm 4
20 May 2025Priya SinghalHead of DevelopmentSellplanned in advance (10b5-1)3,806$126.25$481KForm 4
5 May 2025Caroline DorsaDirectorBuy1,235$122.72$152KForm 4

1,044 institutions reported shares at the end of Q3 2026, 95% of the shares outstanding; 88 opened a position, 68 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)16.8M11.4%$3.8B-1.4M-7.9%
BlackRock, Inc.16.1M10.9%$3.6B+103K+0.6%
Primecap Management Co15.2M10.3%$3.4B+42K+0.3%
Vanguard Capital Management LLC9.7M6.54%$2.2B+20K+0.2%
State Street Corp7.6M5.12%$1.7B+218K+3.0%
Vanguard Portfolio Management LLC6.6M4.45%$1.5B-33K-0.5%
Geode Capital Management, LLC4.5M3.05%$1.0B+58K+1.3%
Wellington Management Group LLP3.5M2.34%$781.3M+341K+11%
Morgan Stanley2.5M1.70%$566.1M+95K+3.9%
JPMorgan Chase & Co2.0M1.38%$463.0M+216K+12%

Company events

All 39 company events

In 12 months: 2 director or officer changes, 2 major agreements, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
14 May 2026Signed a major agreement; Completed an acquisition or asset saleSame filing: took on new debt8-K
31 Mar 2026Signed a major agreement8-K
11 Mar 2026Director or officer change8-K
11 Feb 2026Director or officer change8-K
15 Jan 2025Director or officer change8-K
30 Oct 2024Director or officer change8-K
12 Sep 2024Director or officer change8-K
14 Aug 2024Signed a major agreement; A major agreement endedSame filing: took on new debt8-K

Reported lobbying spend: $880K in Q3 2026, $1.1M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
17 Dec 2025EndedJeffrey J. Kimbell & Associates, Inc.for Biogen Inc.Issues related to Medicare Part B and Part D; Issues related to the pharmaceutical industryMedicare/Medicaid, Health issuesFiling
1 Jun 2025NewDla Piper LLP (US)for Biogen, Inc.Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax poliMED, Health issuesFiling
31 Dec 2023EndedThorn Run Partnersfor BiogenLegislation that would alter payment policies under Medicare Part B for drugs and biologics. Issues pertaining to Medicare Part D.; Biosimilar policies.Medicare/Medicaid, Health issuesFiling
23 Feb 2023EndedClyburn Consulting, LLCfor BiogenIssues related to treatment of neurological diseases and disordersHealth issuesFiling
30 Dec 2022EndedCapitol Counsel LLCfor Biogen, Inc.Medicare beneficiary access to treatments for Alzheimers disease, including Medicare Part B access issues, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. No: 117-169), including Subtitle B - Prescription Drug Pricing Reform, Part 1 - Lowering Prices through Drug; Patient access to treatments for Alzheimers disease, and 340B Drug Pricing Program related issues.Medicare/Medicaid, Health issuesFiling
4 Mar 2022NewClyburn Consulting, LLCfor BiogenAlzheimer's disease and treatmentHealth issuesFiling
1 Jan 2021EndedAlston & Bird LLPfor Biogen, Inc.Not statedFiling
1 May 2020NewCapitol Counsel LLCfor Biogen, Inc.Medicare beneficiary and patient access to treatments for Alzheimers disease, ALS, and other neurological conditions.Medicare/Medicaid, Health issuesFiling

The 5 newest of 387 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Mar 2020confirmed

Confirmed across sources Attention and Institutional holdings

Biogen (BIIB): saw 118 13F filers open a new position in the quarter ended 31 Dec 2019, 2.3× the same quarter last year, while it drew 13K Wikipedia page views in the week of 9 Mar 2020, 5.4× the same week last year. Two unrelated kinds of activity within 28 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2020
  • Attention: Wikipedia attention spike, became public on 17 Mar 2020
2017-12-31: 732018-03-31: 742018-06-30: 622018-09-30: 1212018-12-31: 522019-03-31: 952019-06-30: 642019-09-30: 642019-12-31: 118
The quarter ended 31 Dec 2019 against the 8 quarters before it. this quarterearliernormal: 68.5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 14 Feb 2020

Biogen saw 118 13F filers open a new position in the quarter ended 31 Dec 2019, 2.3× the same quarter last year.

This period
118 (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
68.5
Typical spread (median absolute deviation)
6
How far from its usual level
+5.6
Same quarter last year
52
History used
2,283 days
2017-12-31: 732018-03-31: 742018-06-30: 622018-09-30: 1212018-12-31: 522019-03-31: 952019-06-30: 642019-09-30: 642019-12-31: 118
the quarter ended 31 Dec 20198 earlier quartersnormal: 68.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Attention: Wikipedia attention spike became public on 17 Mar 2020

Biogen drew 13K Wikipedia page views in the week of 9 Mar 2020, 5.4× the same week last year.

This period
13K (the week of 9 Mar 2020)
Normal week (median of 26 earlier)
3,744
Typical spread (median absolute deviation)
444
How far from its usual level
+13.5
Same week last year
2,346
History used
439 days
2019-09-09: 2,4612019-09-16: 1,9402019-09-23: 2,1962019-09-30: 3,9002019-10-07: 2,6422019-10-14: 3,5782019-10-21: 10K2019-10-28: 4,0362019-11-04: 3,7952019-11-11: 2,9162019-11-18: 3,6492019-11-25: 3,7362019-12-02: 4,4542019-12-09: 4,1162019-12-16: 3,9542019-12-23: 2,5692019-12-30: 3,4372020-01-06: 3,2292020-01-13: 3,6502020-01-20: 3,7532020-01-27: 3,0862020-02-03: 4,0592020-02-10: 6,0612020-02-17: 4,6942020-02-24: 3,9162020-03-02: 6,2242020-03-09: 13K
the week of 9 Mar 202026 earlier weeksnormal: 3,744

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 14 May 2026Filings record

    Completed an acquisition or asset sale

  2. 11 Mar 2026Filings record

    Director or officer change

  3. 18 Feb 2026Insiders record

    Murphy Nicole (Head of Pharm Ops and Tech) bought 3 shares of BIIB ($585) (dated 17 Feb 2026)

  4. 13 Feb 2026Institutional holdings record

    Boston Partners opened a $303.0M position (2025Q4 13F)

  5. 11 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 11 Feb 2026Filings record

    Director or officer change

  7. 9 Jan 2026Lobbying record

    BIOGEN INC.: lobbying engagement terminated (JEFFREY J. KIMBELL & ASSOCIATES, INC.) (dated 17 Dec 2025)

  8. 25 Dec 2025Short interest and volume change

    had 6.6M shares sold short in the 15 Dec 2025 report, 2.6× the same report last year.

    Same report last year: 2.6M; its normal report is 3.8M.

    See the evidence
    This period
    6.6M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    473K
    How far from its usual level
    +3.9
    Same report last year
    2.6M
    History used
    2,908 days
    2024-12-13: 2.6M2024-12-31: 3.7M2025-01-15: 3.8M2025-01-31: 3.7M2025-02-14: 3.9M2025-02-28: 3.7M2025-03-14: 3.3M2025-03-31: 3.3M2025-04-15: 3.4M2025-04-30: 3.2M2025-05-15: 3.3M2025-05-30: 3.8M2025-06-13: 3.4M2025-06-30: 4.0M2025-07-15: 3.9M2025-07-31: 4.0M2025-08-15: 4.2M2025-08-29: 4.7M2025-09-15: 5.1M2025-09-30: 4.9M2025-10-15: 5.2M2025-10-31: 5.6M2025-11-14: 6.1M2025-11-28: 6.8M2025-12-15: 6.6M
    the 15 Dec 2025 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 10 Dec 2025Short interest and volume change

    had 6.8M shares sold short in the 28 Nov 2025 report, 2.5× the same report last year.

    Same report last year: 2.7M; its normal report is 3.8M.

    See the evidence
    This period
    6.8M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    416K
    How far from its usual level
    +4.9
    Same report last year
    2.7M
    History used
    2,891 days
    2024-11-29: 2.7M2024-12-13: 2.6M2024-12-31: 3.7M2025-01-15: 3.8M2025-01-31: 3.7M2025-02-14: 3.9M2025-02-28: 3.7M2025-03-14: 3.3M2025-03-31: 3.3M2025-04-15: 3.4M2025-04-30: 3.2M2025-05-15: 3.3M2025-05-30: 3.8M2025-06-13: 3.4M2025-06-30: 4.0M2025-07-15: 3.9M2025-07-31: 4.0M2025-08-15: 4.2M2025-08-29: 4.7M2025-09-15: 5.1M2025-09-30: 4.9M2025-10-15: 5.2M2025-10-31: 5.6M2025-11-14: 6.1M2025-11-28: 6.8M
    the 28 Nov 2025 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 26 Nov 2025Short interest and volume change

    had 6.1M shares sold short in the 14 Nov 2025 report, 2.3× the same report last year.

    Same report last year: 2.7M; its normal report is 3.8M.

    See the evidence
    This period
    6.1M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    406K
    How far from its usual level
    +4.0
    Same report last year
    2.7M
    History used
    2,877 days
    2024-11-15: 2.7M2024-11-29: 2.7M2024-12-13: 2.6M2024-12-31: 3.7M2025-01-15: 3.8M2025-01-31: 3.7M2025-02-14: 3.9M2025-02-28: 3.7M2025-03-14: 3.3M2025-03-31: 3.3M2025-04-15: 3.4M2025-04-30: 3.2M2025-05-15: 3.3M2025-05-30: 3.8M2025-06-13: 3.4M2025-06-30: 4.0M2025-07-15: 3.9M2025-07-31: 4.0M2025-08-15: 4.2M2025-08-29: 4.7M2025-09-15: 5.1M2025-09-30: 4.9M2025-10-15: 5.2M2025-10-31: 5.6M2025-11-14: 6.1M
    the 14 Nov 2025 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 1 Jul 2025Lobbying record

    BIOGEN, INC.: new lobbying registration (DLA PIPER LLP (US)) (dated 1 Jun 2025)

  12. 6 May 2025Insiders record

    DORSA CAROLINE (director) bought 1,235 shares of BIIB ($151,559) (dated 5 May 2025)

  13. 22 Jan 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MAN']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6273167
  14. 15 Jan 2025Filings record

    Director or officer change

  15. 30 Oct 2024Filings record

    Director or officer change

  16. 12 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 12 Sep 2024Filings record

    Director or officer change

  18. 14 Aug 2024Filings record

    A major agreement ended

  19. 23 Jul 2024Lobbying change

    reported $1.7M of lobbying spend for the quarter ended 30 Jun 2024, 2.0× the same quarter last year.

    Same quarter last year: $830K; its normal quarter is $940K.

    See the evidence
    This period
    $1.7M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $940K
    Typical spread (median absolute deviation)
    $45K
    How far from its usual level
    +7.8
    Same quarter last year
    $830K
    History used
    5,479 days
    2022-06-30: $940K2022-09-30: $900K2022-12-31: $900K2023-03-31: $990K2023-06-30: $830K2023-09-30: $1.1M2023-12-31: $940K2024-03-31: $1.1M2024-06-30: $1.7M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $940K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  20. 21 Feb 2024Insiders record

    Rowinsky Eric K (director) bought 455 shares of BIIB ($101,256) (dated 20 Feb 2024)

  21. 23 Jan 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TRA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12615662
  22. 22 Jan 2024Lobbying record

    BIOGEN: lobbying engagement terminated (THORN RUN PARTNERS) (dated 31 Dec 2023)

  23. 8 Nov 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 8 Nov 2023Filings record

    Director or officer change

  25. 10 Aug 2023Short interest and volume change

    had 3.4M shares sold short in the 31 Jul 2023 report, 1.8× the same report last year.

    Same report last year: 1.9M; its normal report is 2.1M.

    See the evidence
    This period
    3.4M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    200K
    How far from its usual level
    +4.5
    Same report last year
    1.9M
    History used
    2,040 days
    2022-07-29: 1.9M2022-08-15: 2.0M2022-08-31: 1.9M2022-09-15: 2.1M2022-09-30: 2.7M2022-10-14: 2.5M2022-10-31: 2.5M2022-11-15: 2.4M2022-11-30: 2.5M2022-12-15: 2.1M2022-12-30: 1.7M2023-01-13: 1.9M2023-01-31: 1.9M2023-02-15: 1.7M2023-02-28: 1.8M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.3M2023-05-15: 3.0M2023-05-31: 2.5M2023-06-15: 2.2M2023-06-30: 2.1M2023-07-14: 2.6M2023-07-31: 3.4M
    the 31 Jul 2023 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 18 Apr 2023Lobbying record

    BIOGEN: lobbying engagement terminated (CLYBURN CONSULTING, LLC) (dated 23 Feb 2023)

  27. 9 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 9 Mar 2023Filings record

    Director or officer change (dated 8 Mar 2023)

  29. 20 Jan 2023Lobbying record

    BIOGEN, INC.: lobbying engagement terminated (CAPITOL COUNSEL LLC) (dated 30 Dec 2022)

  30. 10 Nov 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 10 Nov 2022Filings record

    Director or officer change

  32. 21 Jun 2022Filings record

    Director or officer change

  33. 3 May 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 3 May 2022Filings record

    Director or officer change

  35. 11 Apr 2022Lobbying record

    BIOGEN: new lobbying registration (CLYBURN CONSULTING, LLC) (dated 4 Mar 2022)

  36. 31 Jan 2022Filings record

    Director or officer change

  37. 17 Nov 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 17 Nov 2021Filings record

    Director or officer change

  39. 15 Jun 2021Attention change

    drew 20K Wikipedia page views in the week of 7 Jun 2021, 9.0× the same week last year.

    Same week last year: 2,180; its normal week is 1,950.

    See the evidence
    This period
    20K (the week of 7 Jun 2021)
    Normal week (median of 26 earlier)
    1,950
    Typical spread (median absolute deviation)
    185
    How far from its usual level
    +64.2
    Same week last year
    2,180
    History used
    894 days
    2020-12-07: 3,4122020-12-14: 2,4722020-12-21: 1,4022020-12-28: 1,7102021-01-04: 2,1422021-01-11: 2,2662021-01-18: 2,1222021-01-25: 2,4932021-02-01: 2,5382021-02-08: 2,0802021-02-15: 1,8552021-02-22: 1,8382021-03-01: 2,1222021-03-08: 2,0012021-03-15: 1,9602021-03-22: 1,8192021-03-29: 1,5972021-04-05: 1,7722021-04-12: 1,8242021-04-19: 1,9392021-04-26: 1,9392021-05-03: 1,7472021-05-10: 1,5062021-05-17: 1,7552021-05-24: 2,1022021-05-31: 2,8992021-06-07: 20K
    the week of 7 Jun 202126 earlier weeksnormal: 1,950

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  40. 20 Apr 2021Lobbying record

    BIOGEN, INC.: lobbying engagement terminated (ALSTON & BIRD LLP) (dated 1 Jan 2021)

Showing the newest 40 of 141 entries; narrow the window or the kind of data to see older ones.

Not listed: 185 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000875045
Ticker
BIIB
Domain
biogen.com
Employer name
BIOGEN, INC. (1 unverified)
Hq location
MA|CAMBRIDGE|02142 (1 unverified)
Lobbying client
biogen, biogen idec
Name
Alcyone Therapeutics, Inc, BIIB Colombia S.A.S, Biogen Arabia Limited, Biogen (Argentina) SRL and 86 more
Wikidata
Q864338
Wikipedia
Biogen
  • DOL H-1B labor condition applications and PERM certifications1285 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)67 records, 279 data points30 Jun 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings4 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)153 records27 Jan 2016 to 28 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1289 data points31 Dec 2006 to 26 Oct 2026
  • SEC Form 4 insider transactions76 records, 284 data points10 Feb 2016 to 5 Aug 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4174 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026